NEXGEL Earnings Call Transcripts
Fiscal Year 2026
-
The acquisition of Celularity's Degenerative Wound segment, backed by Sequence LifeScience, is expected to triple revenue, be immediately accretive, and transform the business into a diversified medical technology platform with strong growth prospects.
Fiscal Year 2025
-
Q3 2025 revenue was flat year-over-year at $2.9M, but gross margin improved to 42.4% and adjusted EBITDA loss narrowed. Strong contract manufacturing and new product launches are expected to drive a record Q4, with full-year revenue guidance of $12M–$12.5M.
-
Significant growth achieved through strategic partnerships, acquisitions, and innovative hydrogel products. Expansion into new markets and product lines, strong revenue growth, and robust R&D pipeline position the company for continued success.
-
Q2 2025 saw revenue double year-over-year to $2.9M, with gross margin rising to 43.6% and narrowing losses. Strong growth in both contract manufacturing and consumer products, expanded partnerships, and new product launches support reaffirmed 2025 guidance for $13M revenue and positive EBITDA.
-
Q1 2025 revenue surged 121% year-over-year to $2.81 million, with gross margin rebounding to 42.4%. Both contract manufacturing and consumer-branded products, especially Silly George, drove growth. 2025 guidance remains at $13 million revenue and cash flow positivity, with strong product pipeline and manageable tariff risks.
-
Hydrogel technology drives growth across medical, consumer, and contract manufacturing divisions, with strong partnerships, product innovation, and expanding U.S. operations. Margin management and platform-specific marketing support continued revenue growth and a path to profitability.
Fiscal Year 2024
-
Record revenue growth in 2024 was driven by strong performance in both branded consumer products and contract manufacturing, with new partnerships and product launches fueling expansion. Guidance for 2025 targets at least $13 million in revenue and positive EBITDA.
-
The presentation detailed strong revenue growth driven by new product launches, strategic acquisitions, and major partnerships, including nationwide distribution of SilverSeal and an upcoming supply deal with AbbVie. Expansion into new digital and retail platforms is planned, with a focus on achieving cash flow positivity.
-
Record Q3 revenue and gross margin growth driven by branded consumer and contract manufacturing segments, with Silly George and Cintas partnerships fueling momentum. Cash flow positive is within reach, and Q4 is expected to surpass $3 million in revenue.
-
Record Q2 revenue driven by branded products and Silly George acquisition, with strong guidance for Q3 and Q4. Facility expansion and new partnerships, including Cintas and AbbVie, position the business for significant growth and potential positive cash flow.